BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 26, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 25, 2007
View Archived Issues
Adnexus Nixes IPO Route, Opts For $430M BMS Exit
Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today)
Read More
Celgene Paying Array $40M Up Front For Drug Discovery
Read More
Ariad Hoping To 'Succeed' In Phase III Study Of Deforolimus
Read More
Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug
Read More
Elixir Aiming For Public Markets With $86M IPO
Read More
Other News To Note
Read More
Clinic Roundup
Read More
